Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Shattuck Labs, Inc. (STTK)

Shattuck Labs Q2 net loss widens to $15.2 million; cash rises to $208.3 million

Mixed Impact 3 of 5 earnings Written later

Shattuck Labs reported no revenue for the quarter ended June 30, 2026, and a net loss of $15.2 million, up from $12.5 million a year earlier. Loss per share narrowed to $0.12 from $0.24, while the weighted-average share count rose to about 129.8 million from about 51.0 million. Cash, cash equivalents and short-term investments were $208.3 million, which the company says should fund operations into 2029.

Key points

  • Net loss was $15.2 million, or $0.12 per share, for Q2 2026, versus $12.5 million, or $0.24 per share, for Q2 2025.
  • R&D expenses rose to $11.7 million from $8.7 million; G&A expenses were $4.5 million versus $4.4 million.
  • Cash and short-term investments were $208.3 million at June 30, 2026, versus $50.5 million a year earlier.
  • The RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease is expected to start in Q3 2026; the company also cites a $86.2 million underwritten offering and $57.1 million from warrant exercises.

The filing

CompanyShattuck Labs, Inc. (STTK)
Form8-K, current report
Filed with the SECAug 11, 2026, 6:59 AM ET
Accession number0001628280-26-055484

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.